Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (387)

« Back to Publications

Spatial Robustness of Prostate Cancer Biomarkers Evaluated by Spatial Transcriptomics.

Taylor KG. et al, (2026), Prostate

Long-term outcomes of cribriform-positive and cribriform-negative prostate cancer treated with radical prostatectomy in the ProtecT trial.

Sushentsev N. et al, (2026), BJU Int

Assessing the effects of a 3D pathology tissue-processing workflow on downstream molecular analyses.

Baraznenok E. et al, (2026)

Genomic risk model to implement precision prostate cancer screening in clinical care: the ProGRESS study.

Vassy JL. et al, (2026), Nat Cancer, 7, 352 - 367

Circulating tumour cells as a window into lethality in prostate cancer.

Abusamra SM. et al, (2026), Nat Rev Urol

Nicotinamide N-Methyl Transferase (NNMT) Sustains Innate Sensitivity to NAMPT Inhibition in YAP-dependent Stem-like/Mesenchymal Prostate Cancer.

Carreira ÁSA. et al, (2026), Int J Biol Sci, 22, 1126 - 1141

Abstract PR013: Comprehensive spatial profiling of prostate cancer metastasis: Mapping clonal evolution, microenvironment dynamics, and early metastatic markers

He M. et al, (2026), CANCER RESEARCH, 86, PR13 - PR13

Integrating multi-omic datasets investigating stress response biology decodes prostate cancer dynamic disease progression and places IRE1 activity at the epicentre of acquired treatment resistance

Doultsinos D. et al, (2026), CANCER RESEARCH, 86

Active Monitoring, Surgery, and Radiotherapy for Cribriform-Positive and Cribriform-Negative Prostate Cancer: A Secondary Analysis of the PROTECT Randomized Clinical Trial.

Sushentsev N. et al, (2025), JAMA Oncol, 11, 1512 - 1517

Figure 4 from Attenuating Adaptive VEGF-A and IL8 Signaling Restores Durable Tumor Control in AR Antagonist–Treated Prostate Cancers

Maxwell PJ. et al, (2025)

Figure 2 from Attenuating Adaptive VEGF-A and IL8 Signaling Restores Durable Tumor Control in AR Antagonist–Treated Prostate Cancers

Maxwell PJ. et al, (2025)

Figure 1 from Attenuating Adaptive VEGF-A and IL8 Signaling Restores Durable Tumor Control in AR Antagonist–Treated Prostate Cancers

Maxwell PJ. et al, (2025)

Figure 5 from Attenuating Adaptive VEGF-A and IL8 Signaling Restores Durable Tumor Control in AR Antagonist–Treated Prostate Cancers

Maxwell PJ. et al, (2025)

Figure 3 from Attenuating Adaptive VEGF-A and IL8 Signaling Restores Durable Tumor Control in AR Antagonist–Treated Prostate Cancers

Maxwell PJ. et al, (2025)

3D pathology-guided microdissection.

Hsieh H-C. et al, (2025)

Load More

1
2
3
4
5
6
7
...
»